Lilly’s Mirikizumab Shows Superiority Vs. Cosentyx In Psoriasis

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Lilly plans to file the anti-IL-23 antibody for approval in psoriasis based on two Phase III trials. The latest data head-to-head against IL-17 inhibitor Cosentyx may guide physicians on how to treat patients.

Two female fencing athletes fight on professional sports arena with spectators and lense-flares. Women wear unbranded sports clothes.
Lilly's mirikizumab showed superiority versus Consentyx in three 52-week measures

Eli Lilly and Company is ready to file its interleukin-23 inhibitor mirikizumab with the US Food and Drug Administration for approval in moderate-to-severe plaque psoriasis after reporting results from a second successful Phase III study on 17 July. The OASIS-2 trial showed that the candidate was non-inferior to the interleukin-17 inhibitor Cosentyx (secukinumab) on three endpoints at 16 weeks and superior to Novartis AG’s market-leading biologic at 52 weeks on those same endpoints.

Lilly already has its own IL-17 therapy, Taltz (ixekizumab), on the market for psoriasis but the company’s strategy is to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D